Impact of resolved hepatitis B virus infection on clinical outcomes in patients with diffuse large B-cell lymphoma: a supplementary analysis of JCOG0601. (PubMed, Int J Hematol) - Sep 28, 2026 - "HBV reactivation occurred in five anti-HBc-positive patients. Baseline anti-HBc positivity was more common in older patients but was not associated with inferior outcomes in HBsAg-negative DLBCL treated with rituximab-containing CHOP-based therapy.Clinical trial registration: JCOG0601 was registered in the Japan Registry of Clinical Trials (jRCTs031180139, date of registration; February 20, 2019)."
Clinical data • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatitis B • Infectious Disease • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|
|
Dai Maruyama; Hirokazu Nagai; Junya Makiyama; Ken Ohmachi; Kiyoshi Ando; Kunihiro Tsukasaki; Ryunosuke Machida; Shigeru Kusumoto; Shinya Hagiwara; Tomohiro Kinoshita; Wataru Munakata
|